Release
📈 Stocks
—
📊 Neutral
Paradigm Unveils SD-101 Zorblesia for Epidermolysis Bullosa Treatment
(just now)
Paradigm introduces Zorblesia (SD-101), a novel topical treatment targeting wounds and lesions in patients suffering from the three major subtypes of Epidermolysis…